Biology Reference
In-Depth Information
161. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R,
Minna JD, et al. Methylation profiles of sporadic ovarian tumors
and nonmalignant ovaries from high-risk women.
Clin Cancer Res
2002;8(11):3324
174. Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A,
Eve PD, et al. Preclinical pharmacology, antitumor activity, and
development of pharmacodynamic markers for the novel, potent
AKT inhibitor CCT128930.
Mol Cancer Ther
2011;10(2):360
31.
162. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Meth-
ylation of the BRCA1 promoter is associated with decreased
BRCA1 mRNA levels in clinical breast cancer specimens.
Carci-
nogenesis
2000;21(9):1761
e
71.
175. Wang HM, Cheng KC, Lin CJ, Hsu SW, Fang WC, Hsu TF, et al.
Obtusilactone A and (-)-sesamin induce apoptosis in human lung
cancer cells by inhibiting mitochondrial Lon protease and acti-
vating DNA damage checkpoints.
Cancer Sci
101(12):2612
e
5.
163. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, et al.
Expression of BRCA1 protein in benign, borderline, and malig-
nant epithelial ovarian neoplasms and its relationship to meth-
ylation and allelic loss of the BRCA1 gene.
J Pathol
2004;202(2):
215
e
20.
176. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose)
polymerase (PARP) inhibitors: Exploiting a synthetic lethal
strategy in the clinic.
CA
61(1):31
e
49.
177. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, Hoon DS.
Association of circulating tumor cells with serum tumor-related
methylated DNA in peripheral blood of melanoma patients.
Cancer Res
2006;66(12):6111
e
23.
164. Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E, van
Diest PJ. Methylation profiles of hereditary and sporadic ovarian
cancer.
Histopathology
2010;57:363
e
7.
178. Pierce DW, Hom-Booher N, Otsuka AJ, Vale RD. Single-molecule
behavior of monomeric and heteromeric kinesins.
Biochemistry
1999;38(17):5412
e
70.
165. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM,
et al. Xenografts of primary human gynecological tumors grown
under the renal capsule of NOD/SCID mice show genetic
stability during serial transplantation and respond to cytotoxic
chemotherapy.
Gynecol Oncol
2008;110(2):256
e
21.
179. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV,
et al. Functional evaluation and cancer risk assessment of BRCA2
unclassified variants.
Cancer Res
2005;65(2):417
e
64.
166. Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD,
Schnitt SJ, et al. DNA repair protein biomarkers associated with
time to recurrence in triple-negative breast cancer.
Clin Cancer Res
2010;16(23):5796
e
26.
180. Ohashi A, Zdzienicka MZ, Chen J, Couch FJ. Fanconi anemia
complementation group D2 (FANCD2) functions independently
of BRCA2- and RAD51-associated homologous recombination in
response to DNA damage.
J Biol Chem
2005;280(15):14877
e
804.
167. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE,
Lingen MW. Pilot study examining tumor expression of RAD51
and clinical outcomes in human head cancers.
e
83.
181. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE,
Djureinovic T, et al. Poly(ADP-ribose) polymerase is hyper-
activated in homologous recombination-defective cells.
Cancer
Res
2010;70:5389
e
Int
J Oncol
9.
168. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, et al.
High-level expression of Rad51 is an independent prognostic
marker of survival in non-small-cell lung cancer patients.
Br J
Cancer
2005;93(1):137
2006;28(5):1113
e
98.
182. Horsman MR. Nicotinamide and other benzamide analogs as
agents for overcoming hypoxic cell radiation resistance in
tumours. A review.
Acta Oncol (Stockh)
1995;34(5):571
e
87.
183. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel
biology-based approach in radiotherapy.
Lancet Oncol
2002;3(12):
728
e
43.
169. Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW,
et al. Rad51 overexpression contributes to chemoresistance in
human soft tissue sarcoma cells: a role for p53/activator
protein 2 transcriptional regulation.
Mol Cancer Ther
2007;6(5):
1650
e
37.
184. Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD,
Kamjoo M, et al. Vasoactivity of AG014699, a clinically active
small molecule inhibitor of poly(ADP-ribose) polymerase:
a contributory factor to chemopotentiation in vivo?
Clin Cancer
Res
2009;15(19):6106
e
60.
170. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z,
Peock S, et al. Overexpression of RAD51 occurs in aggressive
prostatic cancer.
Histopathology
2009;55(6):696
e
12.
185. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, et al.
Activiation of poly(ADP-ribose) polymerase contributes to
development of doxorubicin-induced heart failure.
J Pharmacol
Exper Ther
2002;300:862
e
704.
171. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S,
et al. Over-expression of wild-type Rad51 correlates with histo-
logical grading of invasive ductal breast cancer.
Int J Cancer
2000;88(6):907
e
7.
186. Joseph I, Fergusin D, Palma J, Godzicki L, Rodriguez LE, Frost D,
et al. Poly(ADP-ribose) polymerase inhibitor, ABT-472, enhances
antitumor activity of doxorubicin in human xenograft models
and protects against drug-induced cardiac toxicity.
EJC Suppl
2004;2(8):473.
187. Chen G, Pan QC. Potentiation of the antitumor activity of
cisplatin in mice by 3-aminobenzamide and nicotinamide.
Cancer
Chemother Pharmacol
1988;22(4):303
e
13.
172. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop DK.
RAD51 up-regulation bypasses BRCA1 function and is a common
feature of BRCA1-deficient breast tumors.
Cancer Res
2007;67(20):
9658
e
65.
173. Soderlund K, Stal O, Skoog L, Rutqvist LE, Nordenskjold B,
Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good
response to radiotherapy in early breast cancer.
Int J Radiat Oncol
Biol Phys
2007;68(1):50
e
8.
e
e
7.
